5-(2-methoxyphenyl)thiophene-2-carboxylic acid | 844897-41-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 5-(2-methoxyphenyl)thiophene-2-carboxylic acid
• CAS: 844897-41-2
• 化学式: C₁₂H₁₀O₃S
• 分子量: 234.276
• InChiKey: LZWPHBZWYOWQBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  74.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(2-methoxyphenyl)thiophene-2-carboxylic acid 、 N¹-(2-((3S,5R)-3,5-dimethyl-1-piperazinyl)-5-fluoro-4-pyrimidinyl)-3-methoxy-benzene-1,4-diamine 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-(4-((2-((3S,5R)-3,5-dimethyl-1-piperazinyl)-5-fluoro-4-pyrimidinyl)amino)-2-methoxyphenyl)-5-(2-methoxyphenyl)-thiophene-2-carboxamide
  参考文献：
  名称：

  Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors ofN-Phenyl-4-pyrimidinamine Derivatives Bearing Potent Activities against Tumor Growth

  摘要：

  The transcriptional repressor B-cell lymphoma 6 (BCL6) is frequently misregulated in diffuse large B-cell lymphoma (DLBCL) and has emerged as an attractive drug target for the treatments of lymphoma. In this article, a series of N-phenyl-4-pyrimidinamine derivatives were designed and synthesized as potent BCL6 inhibitors by optimizing hit compound N-4-(3-chloro-4-methoxyphenyl)-N-2-isobutyl-5-fluoro-2,4-pyrimidinediamine on the basis of the structure-activity relationship. Among them, compound 14j displayed the most potent activities, which significantly blocked the interaction of BCL6 with its corepressors, reactivated BCL6 target genes in a dose-dependent manner, and had better effects compared with the two positive controls. Further studies indicated that a low dose of 14j could effectively inhibit germinal center formation. More importantly, 14j not only showed potent inhibition of DLBCL cell proliferation in vitro but also strongly suppressed the growth of DLBCL in vivo.

  DOI：

  10.1021/acs.jmedchem.9b01618
• 作为产物：
  描述：

  5-溴-2-羧基噻吩 、 2-甲氧基苯基硼酸 在 乙二胺四乙酸 、 potassium carbonate 、 palladium dichloride 作用下， 反应 2.0h， 以84%的产率得到5-(2-methoxyphenyl)thiophene-2-carboxylic acid
  参考文献：
  名称：

  Pd-EDTA是水中铃木-宫浦反应的有效催化剂

  摘要：

  PdCl 2 -EDTA络合物1是在20-100°C的水中，芳基和杂芳基卤化物与芳基（杂芳基）硼酸的Suzuki-Miyaura反应的有效催化剂。芳基碘化物和溴化物进行交叉耦合，其周转数（TON）高达97,000，周转频率（TOF）高达582,000 h -1。

  DOI：

  10.1016/j.tetlet.2005.06.085

文献信息

• [EN] CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE LA CYSTEINE PROTEASE
  申请人：AXYS PHARM INC

  公开号：WO2003097617A1

  公开（公告）日：2003-11-27

  The present invention is directed to compounds that are inhibitors of cysteine protease, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及一种抑制半胱氨酸蛋白酶的化合物，特别是包括B、K、L、F和S型半胱氨酸蛋白酶，在治疗由这些蛋白酶介导的疾病中具有用途。本发明涉及包括这些化合物的药物组合物和其制备方法。
• Cyanomethyl derivatives as cysteine protease inhibitors
  申请人：Graupe Michael

  公开号：US20060122184A1

  公开（公告）日：2006-06-08

  The present invention is directed to cyanomethyl derivatives that are inhibitors of cysteine protease, in particular, cathepsin B, K, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及氰甲基衍生物，其是半胱氨酸蛋白酶的抑制剂，特别是对于B、K、F和S型的卡特普辛，因此可用于治疗由这些蛋白酶介导的疾病。本发明还涉及包含这些化合物的制药组合物和其制备过程。
• Cysteine protease inhibitors
  申请人：Graupe Michael

  公开号：US20050288336A1

  公开（公告）日：2005-12-29

  The present invention is directed to compounds that are inhibitors of cysteine protease, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及一种抑制半胱氨酸蛋白酶的化合物，特别是cathepsin B、K、L、F和S，因此可用于治疗由这些蛋白酶介导的疾病。本发明涉及包含这些化合物的制药组合物和制备它们的过程。
• Tec kinase inhibitors
  申请人：Bentzien Martin Joerg

  公开号：US20050209284A1

  公开（公告）日：2005-09-22

  Disclosed are compounds of formula(I): wherein Ar 1 , Ar 2 , R 1 , R 2 , R 3 , R 4 and X a are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed are processes for preparing these compounds and to pharmaceutical compositions comprising these compounds.

  本发明公开了式(I)的化合物：其中Ar1、Ar2、R1、R2、R3、R4和Xa的定义如下。本发明的化合物抑制Itk激酶，因此可用于治疗涉及炎症、免疫紊乱和过敏症的疾病和病理条件。本发明还公开了制备这些化合物的方法和包含这些化合物的药物组合物。
• CYSTEINE PROTEASE INHIBITORS
  申请人：AXYS PHARMACEUTICALS, INC.

  公开号：EP1503997A1

  公开（公告）日：2005-02-09